During the past decade, MS INCA HC I Hospital do Cancer I conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 3 clinical trials were completed, i.e. on average, 150% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "MS INCA HC I Hospital do Cancer I" are "Lymphoma, Non-Hodgkin" (1 trials), "Myelodysplastic Syndrome" (1 trials), "Non-Small Cell Lung Cancer" (1 trials) and "Tumors" (1 trials). Many other conditions were trialed in "MS INCA HC I Hospital do Cancer I" in a lesser frequency.

Most popular intervention types in "MS INCA HC I Hospital do Cancer I" are "Drug" (4 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Atezolizumab" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody" (1 trials), "Best Supportiv Care (BSC)" (1 trials) and "Lenalidomide" (1 trials). Other intervention names were less common.

The vast majority of trials in "MS INCA HC I Hospital do Cancer I" are 4 trials for "All" genders.

Currently, there are NaN active trials in "MS INCA HC I Hospital do Cancer I". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in MS INCA HC I Hospital do Cancer I, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in MS INCA HC I Hospital do Cancer I, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".